Gateways to Clinical Trials: April 2006

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 28, Issue 3, 2006, Pages 185-206

  Bayes M ^a   Rabasseda, X ^b   Prous, J R ^b  

^a PROUS SCIENCE   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; AMPRENAVIR PHOSPHATE; BOSENTAN; DEXAMETHASONE; DOCETAXEL; ECULIZUMAB; ERLOTINIB; FEBUXOSTAT; GEFITINIB; LENALIDOMIDE; NATALIZUMAB; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PIMECROLIMUS; PREGABALIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; RIBAVIRIN; RITONAVIR; ROTAVIRUS VACCINE; SITAXSENTAN; SORAFENIB; SUNITINIB; TADALAFIL; TEGASEROD; TEMSIROLIMUS; UNINDEXED DRUG; VILDAGLIPTIN; WART VIRUS VACCINE;

ABDOMINAL PAIN; AMYLOIDOSIS; ANEMIA; ATOPIC DERMATITIS; BONE MARROW TUMOR; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CORONARY ARTERY DISEASE; CROHN DISEASE; DIABETIC NEUROPATHY; GASTROENTERITIS; GASTROINTESTINAL STROMAL TUMOR; GOUT; HEMOGLOBINURIA; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERURICEMIA; KIDNEY CANCER; LUNG CANCER; LUNG NON SMALL CELL CANCER; MULTIPLE MYELOMA; MYCOSIS FUNGOIDES; MYELOFIBROSIS; MYELOID METAPLASIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PERIPHERAL NEUROPATHY; POSTHERPETIC NEURALGIA; PULMONARY HYPERTENSION; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; SALIVARY GLAND CANCER; SKIN CANCER; T CELL LYMPHOMA; THROMBOEMBOLISM; VIRUS INFECTION;

CLINICAL TRIALS; HUMANS;

EID: 33745319758     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (133)

1. Tefferi, A. et al. Lenalidomide (CC-5013) treatment for anemia associated with myelofibrosis with myeloid metaplasia. Blood 2005, 106(11): Abst 2583.
2. Dickinson, A.J., Cullen, M.J., Richards, S.J. et al. The effect of eculizumab therapy on red cell response kinetics in patients with paroxysmal nocturnal hemoglobinuria. Blood 2005, 106(11): Abst 1047.
3. Glasser, R.M. et al. Successful treatment of hemolysis and severe anemia without transfusion in a Jehovah's witness PNH patient with the terminal complement inhibitor eculizumab. Blood 2005, 106(11): Abst 3768.
4. Nichol, J.L., Chen, C.-F., Christal, J., Kelly, R., Sergis-Davenport, E., Stepan, D.E. Safety profile of AMG 531 in healthy volunteers and in thrombocytopenic patients with immune thromobocytopenic purpura. Blood 2005, 106(11): Abst 1240.
5. Bussel, J.B. et al. Long-term dosing of AMG 531 is effective and well tolerated in thrombocytopenic patients with immune thrombocytopenic purpura. Blood 2005, 106(11): Abst 220.
6. Patterson, D. et al. The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease. Br J Clin Pharmacol 2005, 60(5): 459.
7. Seibold, J. et al. Sitaxsentan, a selective endothelin-A receptor antagonist, improves exercise capacity in pulmonary arterial hypertension (PAH) associated with connective tissue disease (CTD). Chest 2005, 128(4, Suppl.): 219S.
8. van Wolferen, S.A. et al. Long-term effects of bosentan on the heart and pulmonary hemodynamics in pulmonary arterial hypertension, a comparison study with epoprostenol. Eur Respir J 2005, 26(Suppl. 49): Abst 1337.
9. Dixon, R., Coyne, T. Warfarin management in pulmonary arterial hypertension is similar between bosentan, placebo, and sitaxsentan. Chest 2005, 128(4, Suppl.): 366S.
10. Badesh, D. et al. Sitaxsentan improves time to clinical worsening in patients with pulmonary arterial hypertension. Chest 2005, 128(4, Suppl.): 160S.
11. Bonderman, D. et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Eur Respir J 2005, 26(Suppl. 49): Abst P1831.
12. Craig, T. et al. A multicenter, open-label study of DX-88 in hereditary angioedema. Allergy Clin Immunol Int 2005(Suppl. 1): Abst 1588.
13. Fujita, T. et al. Effect of MKC-733, a 5-HT3 receptor partial agonist, on bowel motility and symptoms in subjects with constipation: An exploratory study. J Clin Pharm Ther 2005, 30(6): 611.
14. Barbeau, M., Kelly, S., Choueri, G., Flook, N. ZA.Q (Zelnorm Advancing Quality of Life) study outcomes: Treatment with tegaserod in a naturalistic setting is associated with reductions in presenteeism and absenteeism. Am J Gastroenterol 2005, 100(9, Suppl.): Abst 766.
15. Pollack, P.P., Rutgeerts, P., Panaccione, R. et al. Maintenance of remission over 1 year in patients with active Crohn's disease treated with adalimumab: Results of a blinded, placebo-controlled study. Am J Gastroenterol 2005, 100(9, Suppl.): Abst 843.
16. Pollack, P.F., Rutgeerts, P., Panaccione, R. et al. Remission and clinical response induced and maintained in patients with active Crohn's disease treated for 1-year open-label with adalimumab. Am J Gastroenterol 2005, 100(9, Suppl.): Abst 858.
17. Robarts, W.S., Van Deventer, S., Targan, S. et al. Natalizumab improves the health related quality of life (HRQOL) in Crohn's disease patients. Am J Gastroenterol 2005, 100(9, Suppl.): Abst 842.
18. Miner, P.B., Kralstein, J., Bottoli, I., Proskin, H.M., Wolff, M., Rodriguez-Stanley, S. An exploratory open label trial of tegaserod in non-erosive GERD patients with incomplete response to PPI's. Am J Gastroenterol 2005, 100(9, Suppl.): Abst 46.
19. Hare, C.B. et al. Clinical experience with nonstandard doses of interferon alfa-2b and ribavirin in the treatment of chronic hepatitis C infection: A retrospective analysis. Curr Ther Res 2005, 66(5): 433.
20. Kamal, S.M. et al. Peginterferon alpha-2b and ribavirin therapy in chronic hepatitis C genotype 4: Impact of treatment duration and viral kinetics on sustained virological response. Gut 2005, 54(6): 858.
21. Malik, A.H., Nelson, S.D., Lindsey, J.L., Angtuaco, T.L., Moore, C.H. Comparison of pegylated interferon alfa-2a and alfa-2b in combination with ribavirin in obese patients with chronic hepatitis C. Am J Gastroenterol 2005, 100(9, Suppl.): Abst 261.
22. Cekic, S., Nicic, B., Zivkovic, M., Kamenov, B., Kamenov, S., Moskovljevic, J. The treatment of seasonal allergic rhinitis with desloratadine. Allergy Clin Immunol Int 2005, (Suppl. 1): Abst 733.
23. Darsow, U., Ring, J., Behrendt, H. et al. Modulation of atopy patch test and skin prick test by pretreatment with 1% pimecrolimus cream. Allergy Clin Immunol Int 2005 (Suppl. 1): Abst 1654.
24. Dispenzieri, A. et al. Lenalidomide has activity in a phase Ii trial in patients with primary systemic amyloidosis. Blood 2005, 106(11): Abst 252.
25. Vesikari, T. et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354(1): 23.
26. Caplivski, D., Salama, C. Development of atazanavir resistance mutations in a clinical setting among patients without evidence of pre-existing protease mutations. Antivir Ther 2005, 10(4, Suppl.): S30.
27. Yerly, S., Perrin, L., Hirschel, B. et al. Clinical validation of atazanavir/ritonavir genotypic resistance score in PI-experienced patients. Antivir Ther 2005, 10(4, Suppl.): S9.
28. Breilh, D., Pellegrin, J.L., Dabis, F. et al. Impact of baseline protease drug mutations on virological response to fosamprenavir/ritonavir-based regimens in anti-retroviral-experienced patients (ZEPHIR study). Antivir Ther 2005, 10(4, Suppl.): S33.
29. Wunderink, R.G. et al. Coagulation status and response to tifacogin in community-acquired pneumonia. Chest 2005, 128(4, Suppl.): 151S.
30. Barr, E., Jansen, K.U., Cavanaugh, P.F., Jr. et al. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: A 2-year randomized controlled clinical trial. Mayo Clin Proc 2005, 80(5): 601.
31. Siffert, J., Emir, B., LaMoreaux, L., Young, J., Sharma, U., Von Raison, F. Efficacy, safety and tolerability characteristics of anti-convulsant pregabalin as a treatment for neuropathic pain: Findings from the analysis of 10 randomised placebo-controlled clinical trials. Epilepsia 2005, 46(Suppl. 6): Abst p244.
32. Guevara-Aguirre, J. et al. A 12-day comparison of preprandial Humulin vs. Oralin in 10 type-1 diabetic subjects receiving baseline glargine insulin therapy. Horm Res 2005, 64(Suppl. 1): Abst P1-552.
33. Gaudiani, L.M. et al. Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients. Diabetes Obes Metab 2005, 7(1): 88.
34. Ristic, S. et al. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: Vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005, 7(6): 692.
35. Becker, M.A. et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005, 353(23): 2450.
36. Millan, M.C., Lopez, M.B., Calvo, I. Anakinra effectively in systemic juvenile idiopathic arthritis non-responding to conventional treatments. Clin Exp Rheumatol 2005, 23(3, Suppl. 37): Abst P-245.
37. Prieur, A.M., Pannier, A., Faye, A., Job-Deslandre, C., Kone-Paut, I., Quartier, P., Quartier, P. IL-Ira (anakinra) treatment in systemic-onset juvenile idiopathic arthritis. Clin Exp Rheumatol 2005, 23 (3, Suppl. 37): Abst P-243.
38. Cosman, F. et al. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 2005, 353(6): 566.
39. Adler, R.A., Petkov, V.I., Williams, M.I., Guyer, J.L. Effect of concomitant statin therapy in bisphosphonate treated patients with osteoporosis. J Bone Miner Res 2005, 20(Suppl. 1): Abst M366.
40. Schildhauer, S. et al. Randomized phase III study in squamous cell carcinoma of the head & neck (SCCHN) using Lipoplatin: First safety results of a multicenter trial. Eur J Cancer Suppl 2005, 3(2): Abst 996.
41. Faivre, S., Delbaldo, C., Vera, K. et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006, 24(1): 25.
42. Oza, A.M. et al. A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or recurrent endometrial cancer-NCIC CTG IND 160. Eur J Cancer Suppl 2005, 3(2): Abst 907.
43. Demetri, G. et al. Sunitinib malate (SU11248) prolongs progression-free and overall survival for GIST patients after failure of imatinib mesylate therapy: Update of a phase III trial. Eur J Cancer Suppl 2005, 3(2): Abst 716.
44. Escudier, B. et al. Randomized phase III trial of the multi-kinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Eur J Cancer Suppl 2005, 3(2): Abst 794.
45. Oosterwijk-Wakka, J.C., Oosterwijk, E., Bleumer, I. et al. A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. J Urol 2006, 175(1): 57.
46. Motzer, R.J., Michaelson, M.D., Redman, B.G. et al. Activity of SV11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24(1): 16.
47. Antonic, M., Andjelkovic, A., Eri, Z., Stanic, J. Multiple lung metastases of salivary gland adenoid cystic carcinoma (ACC) successfully treated with gefitinib: Case report. Lung Cancer (The Netherlands) 2005, 49(Suppl. 2): Abst 75.
48. Kelly, K., Kashala, O., Schiller, J. et al. Phase 2 study of bortezomib plus/minus docelaxel in advanced non-small cell lung cancer (NSCLC). Lung Cancer (The Netherlands) 2005, 49(Suppl. 2): Abst O-084.
49. Komaki, R., Choy, H., Share, R. et al. A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): An interim overall toxicity report of the RTOG 0324 trial. Lung Cancer (The Netherlands) 2005, 49(Suppl. 2): Abst PD-039.
50. Gandara, D.R., Crowley, J.J., Ung, Y. et al. SWOG 0023: A randomized phase III trial of cisplatin/etoposide (PE) plus radiation therapy followed by consolidation docetaxel then maintenance therapy with gefitinib or placebo in patients with locally advanced unresectable stage III non-small cell lung cancer (NSCLC). Lung Cancer (The Netherlands) 2005, 49(Suppl. 2): Abst O-192a.
51. Gandara, D., Gumerlock, P., Mack, P., Lau, D., Lara, P., Davies, A. Overcoming hypothesized antagonism with intermittent dosing of erlotinib in combination with docetaxel (DOC) in non-small cell lung cancer (NSCLC): A phase I study. Lung Cancer (The Netherlands) 2005, 49(Suppl. 2): Abst O-185.
52. Janne, P., Johnson, B., Temel, J. et al. Phase II study of the EGFR tyrosine kinase inhibitor erlotinib (Tarceva) in patients greater than 70 years of age with previously untreated advanced non-small cell lung carcinoma. Lung Cancer (The Netherlands) 2005, 49(Suppl. 2): Abst O-188.
53. Van Zandwijk, N., Baas, P., Van't Veer, L., Boerrigter, L., Nederlof, P. Mutations in the epidermal growth factor receptor (EGFR): Retro- and prospective observations in non-small cell lung cancer (NSCLC) patients (pts) treated with gefitinib. Lung Cancer (The Netherlands) 2005, 49(Suppl. 2): Abst PD-151.
54. Vrdoljak, E., Cufer, T. SIGN: A phase II, open-label, randomized study comparing gefitinib (Iressa) with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Lung Cancer (The Netherlands) 2005, 49(Suppl. 2): Abst PD-070.
55. Manegold, C., Gatzemeier, U., Gahlemann, C., Buchholz, E., Reck, M. An open-label, multi centre phase II, non-comparative trial of ZD1839 monotherapy in chemotherapy-naive patients with stage IV or stage III non-operable non-small cell lung cancer (NSCLC). Lung Cancer (The Netherlands) 2005, 49(Suppl. 2): Abst PD-154.
56. Bonomi, P. Results of a phase 2 trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed/recurrent non-small cell lung cancer (NSCLC). Lung Cancer (The Netherlands) 2005, 49(Suppl. 2): Abst P-460.
57. Hanna, N., Paul, S., Nguyen, B. et al. An exploratory analysis of a phase III study in patients with advanced non-small cell lung cancer (NSCLC): The impact of first-line gemcitabine and platinum therapy on the outcome of second-line therapy with pemetrexed or docetaxel. Lung Cancer (The Netherlands) 2005, 49(Suppl. 2): Abst PD-068.
58. Traynor, A., Schiller, J., Marcotte, S. et al. Combination therapy with gefitinib and fulvestrant (GIF) for women with non-small cell lung cancer (NSCLC). Lung Cancer (The Netherlands) 2005, 49(Suppl. 2): Abst PD-071.
59. Morganti, A., Shreeniwas, R., Coward, J. et al. A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma. Ann Oncol 2005, 16(Suppl. 2): Abst 153P.
60. Castello, G., Scala, S., Ascierto, P.A. et al. Pegylated arginine deiminase treatment of patients with metastatic melanoma: Results from phase I and II studies. J Clin Oncol 2005, 23(30): 7660.
61. Van Zandwijk, N., Dalesio, O., Lieverst, J., Burgers, S., Baas, P. Pemetrexed with or without a platinum compound in patients with malignant mesothelioma: A single "Expanded Access Program" experience. Lung Cancer (The Netherlands) 2005, 49(Suppl. 2): Abst P-392.
62. Ceresoli, G., Bearz, A., Ceribelli, A. et al. A phase II study of pemetrexed and carboplatin as front-line chemotherapy in patients with malignant pleural mesothelioma (MPM). Lung Cancer (The Netherlands) 2005, 49(Suppl. 2): Abst P-428.
63. Ehlen, T.G. et al. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. Int J Gynecol Cancer 2005, 15(6): 1023.
64. Barbieri, C. et al. Treatment of cutaneous T-cell lymphomas with alemtuzumab. J Eur Acad Dermatol Venereol 2005, 19(Suppl. 2): Abst FC08.9.
65. Gotlib, J. et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005, 106(8): 2865.
66. Nagler, A. et al. Phase I clinical trial of CT-011, a humanized monoclonal antibody directed against a B7 family-associated protein, in patients with advanced hematological malignancies. Exp Hematol 2005, 33(7, Suppl. 1): Abst 227.
67. Giles, F. et al. Use of a disease-specific comorbidity index to describe elderly patients with acute myelogenous leukemia (AML) and high risk myelodysplasia (MDS) enrolled in a phase II study of Cloretazine (VNP40101M). Blood 2005, 106(11): Abst 2787.
68. Giles, F. et al. Cloretazine (VNP40101M) is active in elderly untreated poor risk patients with acute myelogenous leukemia (AML) or high risk myelodysplasia (MDS). Blood 2005, 106(11): Abst 2786.
69. Coiffier, B. et al. HuMax CD20 fully human monoclonal antibody in chronic lymphocytic leukemia. Early results from an ongoing phase I/II clinical trial. Blood 2005, 106( 11): Abst 448.
70. Chanan-Khan, A.A. et al. Results of phase II study of lenalidomide (L) {Revlimid} in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood 2005, 106(11): Abst 447.
71. Mavromatis, B. et al. Efficacy and safety of the combination of Genasense (oblimersen sodium, Bcl-2 antisense oligonucleotide), fludarabine and rituximab in previously treated and untreated subjects with chronic lymphocytic leukemia. Blood 2005, 106(11): Abst 2129.
72. Fazili, J., Chaudary, N., Rudraraju, M. Imatinib mesylate (Gleevec) induced hepatitis. Am J Gastroenterol 2005, 100(9, Suppl.): Abst 685.
73. Wetzler, M. et al. Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia (CML) - Cancer and leukemia group B study 10107. Blood 2005, 106(11): Abst 1097.
74. O'Connor, O.A., Heaney, M.L., Schwartz, L. et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006, 24(1): 166.
75. Smith, S., Schwartzberg, L., Levine, A.M. et al. A phase 2 study of the thrombospondin-mimetic peptide ABT-510 in patients with refractory lymphoma. Blood 2005, 106(11): Abst 1493.
76. Duvic, M. et al. Preliminary phase II results of SGN-30 (anti-CD30 monoclonal antibody) in patients with cutaneous anaplastic large cell lymphoma (ALCL). Blood 2005, 106(11): Abst 4802.
77. Forero-Torres, A. et al. SGN-30 (anti-CD30 monoclonal antibody) is active and well tolerated in patients with refractory or recurrent systemic anaplastic large cell lymphoma (ALCL). Blood 2005, 106(11): Abst 3356.
78. Piekarz, R.L. et al. Completion of the first cohort of patients with cutaneous T-cell lymphoma enrolled on a phase II trial of depsipeptide. Blood 2005, 106(11): Abst 231.
79. Querfeld, C. et al. Preliminary results of a phase II study of CC-5013 (lenalidomide, Revlimid) in patients with cutaneous T-cell lymphoma. Blood 2005, 106(11): Abst 3351.
80. D'Amore, F. et al. HuMax-CD4 (zanolimumab), a fully human monoclonal antibody: Early results of an ongoing clinical trial in CD4+ peripheral T-cell lymphoma of non-cutaneous type. Blood 2005, 106(11): Abst 3354.
81. Chanan-Khan, A.A. et al. Phase 1 clinical trial of KOS-953 + bortezomib (BZ) in relapsed refractory multiple myeloma (MM). Blood 2005, 106(11): Abst 362.
82. Zonder, J.A. et al. High incidence of thrombotic events observed in patients receiving lenalidomide (L) + dexamethasone (D) (LD) as first-line therapy for multiple myeloma (MM) without aspirin (ASA) prophylaxis. Blood 2005, 106(11): Abst 3455.
83. Dimopoulos, M.A. et al. Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): Results of a phase 3 study (MM-010). Blood 2005, 106(11): Abst 6.
84. Rajkumar, S.V. et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005, 106(11): Abst 781.
85. Richardson, P. et al. A phase 1 trial of lenalidomide (Revlimid) with bortezomib (Velcade) in relapsed and refractory multiple myeloma. Blood 2005, 106(11): Abst 365.
86. Palumbo, A. et al. Oral Revlimid(R) plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma. Blood 2005, 106(11): Abst 785.
87. Richardson, P. et al. Safety and activity of KOS-953 in patients with relapsed refractory multiple myeloma (MM): Interim results of a phase 1 trial. Blood 2005, 106(11): Abst 361.
88. Yee, K.W.L. et al. Phase I study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2005, 11(18): 6615.
89. Nademanee, A. et al. A phase 1/2 trial of high-dose yttrium-90- ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin's lymphoma. Blood 2005, 106(8): 2896.
90. Niesvizky, R. et al. Multicenter phase II trial of the histone deacetylase inhibitor depsipeptide (FK228) for the treatment of relapsed or refractory multiple myeloma (MM). Blood 2005, 106(11): Abst 2574.
91. Hussein, A. et al. Doxil, vincristine, reduced frequency dexamethasone and Revlimid. A phase I/II trial in advanced relapsed/refractory multiple myeloma patients. Haematologica 2005, 90(Suppl. 1): Abst PO.736.
92. Raza, A. et al. Hematologic improvement (HI) by TLK199 (Telintra(TM)), a novel glutathione analog, in myelodysplastic syndrome: Phase 2 study results. Blood 2005, 106(11): Abst 2520.
93. Cortes, J. et al. Phase II study of lenalidomide (CC-5013, Revlimid) for patients (pts) with myelofibrosis (MF). Blood 2005, 106(11): Abst 377.
94. Dukes, E., Palacios, G., Vera-Llonch, M., Rejas, J., Argumosa, A., Herranz, J.L. Model-based evaluation of the cost-effectiveness of pregabalin, levetiracetam and generic gabapentin versus standard therapy as an add-on anti-epileptic therapy in patients with refractory epilepsy: A Spanish perspective. Epilepsia 2005, 46(Suppl. 6): Abst p240.
95. Almeida, L. et al. A double-blind, add-on, placebo-controlled exploratory trial of eslicarbazepine acetate in patients with partial-onset seizures. Epilepsia 2005, 46(Suppl. 8): Abst 2.229.
96. Barrett, J., Huang, S., Anhut, H., Spiegel, K. Efficacy, safety and tolerability of pregabalin as add-on treatment for partial seizures with or without secondary generalisations: Findings from the analysis of four randomise clinical trials. Epilepsia 2005, 46(Suppl. 6): Abst p242.
97. Porter, R. et al. Randomized, multicenter, dose-ranging trial of retigabine as adjunctive treatment for partial-onset seizures. J Neurol Sci 2005, 238(Suppl. 1): Abst 0160.
98. Roth, T. et al. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med 2005, 6(6): 487.
99. Zornberg, G., Simon, N., Lydiard, B., Baldinetti, F. Anti-convulsant medication, pregabalin, efficaciously treats generalised anxiety disorder (GAD). Epilepsia 2005, 46(Suppl. 6): Abst p245.
100. Potkin, S.G. et al. Asenapine, a novel psychotherapeutic agent with efficacy in positive and negative symptoms during acute episodes of schizophrenia: A randomized, placebo- and risperidone-controlled trial. Neuropsychopharmacology 2005, 30(Suppl. 1): S112.
101. Marder, S.R. et al. Efficacy and tolerability of two fixed dosages of paliperidone extended-release tablets in the treatment of acute schizophrenia: A 6-week placebo-controlled study. Neuropsychopharmacology 2005, 30(Suppl. 1): S200.
102. Kane, J.M. et al. Treatment of patients with acute schizophrenia using paliperidone extended-release tablets: A 6-week placebo-controlled study. Neuropsychopharmacology 2005, 30(Suppl. 1): S191.
103. Arora, S., Niebler, G.E., Williams, M. et al. Randomized, double-blind, placebo-controlled study of armodafinil for the treatment of excessive sleepiness associated with chronic shift work sleep disorder. Neuropsychopharmacology 2005, 30(Suppl. 1): S140.
104. Thomas, S. et al. Constipation and associated intervention in patients with overactive bladder treated with darifenacin or tolterodine. Int Urogynecol J 2005, 16(Suppl. 2): Abst 306.
105. Haab, F., Pertynski, T. Flexible dosing with solifenacin maximizes treatment efficacy and tolerability in patients with overactive bladder syndrome. Int Urogynecol J 2005, 16(Suppl. 2): Abst 315.
106. Chapple, C. et al. Significant improvements in incontinence endpoints in solifenacin treated patients compared to tolterodine ER treated patients in an overactive bladder study (STAR). Int Urogynecol J 2005, 16(Suppl. 2): Abst 265.
107. Abrams, P. et al. Clinical relevance of quality of life data with darifenacin in patients with overactive bladder. Int Urogynecol J 2005, 16(Suppl.2): Abst 304.
108. Abrams, P., Swift, S.E. Solifenacin is effective for the treatment of OAB dry patients: A pooled analysis. Int Urogynecol J 2005, 16(Suppl.2): Abst 157.
109. Garcia, M., Garcia-Alba, M., Garcia-Fantini, M. Different effects of hormone replacement therapy, DHEAS and tibolone on endothelial function in menopausal women with or without cardiovascular risk. Climacteric (Carnforth) 2005, 8(Suppl. 2): Abst 0315.
110. Steel, S., Adlercreutz, H., Bottazzi, M., Albertazzi, P. Effect of pure genistein supplements on bone markers and hot flushes: A randomized, placebo-controlled cross-over trial. Climacteric (Carnforth) 2005, 8(Suppl. 2): Abst 0188.
111. Colli, E. et al. BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: A randomized clinical trial. Eur Urol 2006, 49(1): 82.
112. Baldwin, D.S. et al. Selective serotonin re-uptake inhibitor treatment-emergent sexual dysfunction: Randomised double-blind placebo-controlled parallel-group fixed-dose study of a potential adjuvant compound, VML 670. J Psychopharmacol 2005, 19(5, Suppl.): Abst TD11.
113. Haefner, D., Escher, A., Engelstaetter, R. Low incidence of oropharyngeal adverse events in asthma patients treated with ciclesonide. Eur Respir J 2005, 26(Suppl. 49): Abst P1738.
114. Buhl, R. et al. Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age. Eur Respir J 2005, 26(Suppl. 49): Abst P418.
115. Sagriotis, A., Chang, A., Van-Dyk, M., Bateman, E. A pilot study comparing tiotropium to salmeterol plus fluticasone in moderate COPD. Eur Respir J 2005, 26(Suppl. 49): Abst P851.
116. Melilli, L. et al. Changes in functional ability as measured by DLQI is consistent with clinical response in moderate to severe plaque psoriasis patients treated with adalimumab. J Eur Acad Dermatol Venereol 2005, 19(Suppl. 2): Abst P06.7.
117. van de Kerkhof, P. Efficacy of multiple courses of alefacept in combination with other psoriasis therapies. J Eur Acad Dermatol Venereol 2005, 19(Suppl. 2): Abst P06.92.
118. Langley, R.G. Reduced monitoring of CD4+ T-cell counts during treatment with multiple courses of alefacept alone or in combination with other psoriasis therapies. J Eur Acad Dermatol Venereol 2005, 19(Suppl. 2): Abst P06.98.
119. Ring, J. et al. The safety of efalizumab in patients with moderate-to-severe plaque psoriasis: Results from the CLEAR study beyond 12 weeks. J Eur Acad Dermatol Venereol 2005, 19(Suppl. 2): Abst P06.87.
120. Varigos, G. et al. A 6-month follow-up of 102 patients with severe chronic plaque psoriasis receiving a combined systemic therapy with efalizumab in Australia. J Eur Acad Dermatol Venereol 2005, 19(Suppl. 2): Abst FC07.8.
121. Borris, L., Bauer, K.A., Turpie, A.G.G. et al. Thromboprophylaxis after orthopaedic surgery with an oral, direct factor Xa inhibitor: Pooled results of two phase IIb clinical trials. Blood 2005, 106(11): Abst 277.
122. Kälebo, P., Misselwitz, F., Kakkar, A.K. et al. Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006, 4(1): 121.
123. Eriksson, B.I. et al. YM150, an oral direct factor Xa inhibitor, as prophylaxis for venous thromboembolism in patients with elective primary hip replacement surgery. A dose escalation study. Blood 2005, 106(11): Abst 1865.
124. Gent, M., Misselwitz, F., Kälebo, P. et al. BAY 59-7939: An oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 2005, 3(11): 2479.
125. Winslow, N., Keipert, P., Winslow, R. et al. A multi-center stufy of the safety and efficacy of MP4 (Hemospan (R)) in orthopedic surgery patients. Crit Care Med 2005, 33(12, Suppl.): Abst 24.
126. Ciancio, G. et al. A randomized trial of three renal transplant induction antibodies: Early comparison of tacrolimus. mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 2005, 80(4): 457.
127. Kirchherr, B., Zeier, M., Budde, K., Cohen, D., Legendre, C.H., Rostaing, L. Safety and tolerability of enteric coated mycophenolate sodium in combination with NEORAL and steroids in de novo kidney transplant recipients: 12 months analysis of a prospective trial. Nephrology (Carlton) 2005, 10(Suppl.): Abst T-PO50030.
128. Jenkins, J.M. et al. SB-497115, a novel, oral, small molecule thrombopoietin receptor agonist, increases platelet counts in healthy subjects. Exp Hematol 2005, 33(7, Suppl. 1): Abst 105.
129. Alonso, P.L. et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: Single-blind extended follow-up of a randomised controlled trial. Lancet 2005, 366(9502): 2012.
130. Mueck, W., Zuehlsdorf, M., Becka, M., Kubitza, D. Effects of single-dose BAY 59-7939 - an oral, direct factor Xa inhibitor - in subjects with extreme body weight. Blood 2005, 106(11): Abst 1872.
131. Zuehlsdorf, M., Mueck, W., Becka, M., Kubitza, D. Naproxen has no relevant effect on the safety, tolerability, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - An oral, direct factor Xa inhibitor. Blood 2005, 106(11): Abst 1873.
132. Zuehlsdorf, M., Voith, B., Wensing, G., Becka, M., Kubitza, D. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005, 61(12): 873.
133. Ruiz-Palacios, G.M. et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354(1): 11.